RxDoctor Payments Data

Jean-Pierre Letellier, MD

Family Medicine · Seminole, TXNPI 1235107657

Payments from drug & device makers

$4,273in general payments, 2019–2025

Across 253 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$722
  • Pfizer$537
  • Lucid Diagnostics Inc.$308
  • Novo Nordisk$277
  • Lilly USA, LLC$259
  • AstraZeneca$257
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,273 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$352,867
Medicare patients
452
Services billed
5,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$102,998
OzempicSemaglutide42$45,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$32,144
JardianceEmpagliflozin23$28,766
MounjaroTirzepatide12$13,378
JanuviaSitagliptin Phosphate18$13,069
FarxigaDapagliflozin Propanediol16$11,394
MyrbetriqMirabegron12$10,690
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen439$10,242
VascepaIcosapent Ethyl13$9,320
Breo ElliptaFluticasone/Vilanterol21$8,386
InvokanaCanagliflozin13$7,318
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl38$5,150
Albuterol Sulfate HfaAlbuterol Sulfate164$4,151
Gabapentin220$3,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$537$102,998105 claims
Novo NordiskOzempic$277$45,88042 claims
GSKTrelegy Ellipta, Breo Ellipta$153$40,53059 claims
Boehringer IngelheimJardiance$29$28,76623 claims
Lilly USA, LLCMounjaro$259$13,37812 claims
MerckJanuvia$103$13,06918 claims
AstraZenecaFarxiga$257$11,39416 claims
Johnson & JohnsonInvokana$62$7,31813 claims
AbbVieSynthroid$722$3,58353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Seminole

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →